1415692-60-2

Upstream product

• 1005142-59-5 (2-bromo-5-chloro-4-hydroxymethylphenyl)methanol 
• 1005142-57-3 [4-(acetoxymethyl)-2-bromo-5-chlorophenyl]methyl acetate 
• 1005143-12-3 1-bromo-2,5-bis(bromomethyl)-4-chlorobenzene 
• 85072-44-2 1-bromo-4-chloro-2,5-dimethylbenzene 
• 13061-96-6 dihydroxy-methyl-borane 
• 1005142-67-5 (1S,3′R,4′S,5′S,6′R)-3′,4′,5′-tri(acetoxy)-6′-acetoxymethyl-5-chloro-6-[(4-ethylphenyl)methyl]-3′,4′,5′,6′-tetrahydrospiro-[isobenzofuran-1(3H),2′-[2H]pyran] 

Relevant academic research and scientific papers

Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes

Inhibition of sodium glucose cotransporter 2 (SGLT2) has been proposed as a novel therapeutic approach to treat type 2 diabetes. In our efforts to discover novel inhibitors of SGLT2, we first generated a 3D pharmacophore model based on the superposition o